[Treatment of giant cell arteritis and polymyalgia rheumatica]. / Therapie der Riesenzellarteriitis und Polymyalgia rheumatica.
Z Rheumatol
; 79(2): 175-185, 2020 Mar.
Article
em De
| MEDLINE
| ID: mdl-32078029
ABSTRACT
Patients with untreated active giant cell arteritis (GCA) are at high risk of permanent vision loss. Therefore, treatment with glucocorticoids should be immediately initiated at an initial dose of 40-60â¯mg prednisolone equivalent dose per day. Once remission is achieved, the prednisolone dose should be reduced to 15-20â¯mg within 2-3 months and then to ≤5â¯mg per day within 1 year. Glucocorticoid-sparing treatment with tocilizumab or alternatively methotrexate should be initiated in patients with an increased risk or pre-existing complications of glucocorticoid treatment and patients with relapse. In polymyalgia rheumatica, prednisolone dosages of 15-25â¯mg/day are sufficient. After achieving remission, the dose should then be reduced to 10â¯mg within 4-8 weeks and then to 1â¯mg per month thereafter. Glucocorticoid-sparing treatment with methotrexate should be initiated in patients with an increased risk or existing complications of glucocorticoid treatment, relapse or increased glucocorticoid requirements.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimialgia Reumática
/
Arterite de Células Gigantes
/
Glucocorticoides
Limite:
Humans
Idioma:
De
Revista:
Z Rheumatol
Ano de publicação:
2020
Tipo de documento:
Article